Acurx Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
14/03/2025 13:22
Acurx Pharmaceuticals Inc ACXP.OQ ACXP.O is expected to report results on March 18 for the period ending December 31 2024 LSEG's mean analyst estimate for Acurx Pharmaceuticals Inc is for a loss of 18 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc is $11.57, above its last closing price of $0.46. This summary was machine generated March 14 at 13:22 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln